Drug Metabolism and New Drug Development for Cancers
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 1028
Special Issue Editors
Interests: drug analysis; drug stability; pharmaceutical chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We invite you to contribute to this Special Issue. Cancer is one of the top causes of death worldwide. However, medical sciences do not remain indifferent and the race is on, the primary goal of which is to help patients through the development of new anticancer drugs and treatments. Understanding metabolic pathways and developing new molecules and formulations for drug delivery are only some of the possible weapons in this unequal fight. The path from developing an active ingredient to implementing the drug into clinical practice is long and involves the work of many specialists.
This Special Issue is devoted to Drug Metabolism and New Drug Development for Cancers and aims to publish original articles as well as interesting review articles on the following topics:
- The biochemistry of anticancer molecules.
- The impact of anticancer drugs/substances on metabolism.
- Natural compounds/extracts and plant screening for antineoplastic activity metabolites.
- Studies in pharmaceutical chemistry: drug structure and activity relationships or the development of new molecules.
- Developing new delivery methods for known substances, for example, formulating new nanoforms such as liposomes, micelles, nanospheres, etc.
Additionally, this Special Issue will be a summary of important research in the development of medical sciences.
Prof. Dr. Anna Jelińska
Dr. Szymon Tomczak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- new drug development
- metabolites
- secondary plant metabolites
- drug delivery
- nanoformulation
- anticancer treatment
